Genevieve Laureys

TL;DR: It is demonstrated that heritable mutations of ALK are the main cause of familial neuroblastoma, and that germline or acquired activation of this cell-surface kinase is a tractable therapeutic target for this lethal paediatric malignancy.

TL;DR: Gain of chromosome segment 17q21-qter is an important prognostic factor in children with neuroblastoma and was a significant predictive factor for adverse outcome in univariate analysis and in multivariate analysis.

TL;DR: The loss of chromosome 1p is a strong prognostic factor in patients with neuroblastoma, independently of age and stage, and reliably identifies patients at high risk in stages I, II, and IVS, which are otherwise clinically favorable.

TL;DR: A meta-analysis of 709 neuroblastoma tumors to determine their frequency and mutation spectrum in relation to genomic and clinical parameters, and studied the prognostic significance of ALK copy number and expression found Chromosome 2p gains were associated with a significantly increased ALK expression, which was also correlated with poor survival.

TL;DR: This international, randomised, multi-arm, open-label, phase 3 cooperative group clinical trial of patients with high-risk neuroblastoma aimed to assess event-free survival after high-dose chemotherapy with busulfan and melphalan compared with carboplatin, etoposide, andMelphalan.